July 13, 2019

Rahul Modi, Founder and CEO, Envision

Rahul Modi, Founder and CEO, Envision

Rahul is a health-tech optimist, serial entrepreneur, and biomedical engineer. His affinity for (sensible) innovation is only challenged by his predilection for building customer-obsessed companies. He's a dream-catcher with unbridled curiosity and a strong operator who enjoys delivering value in large markets ripe for change. Humble beginnings not only keep him anchored, but shape the distinct perspective he brings to the table.

More recently, Rahul was the director and founding member of EyeNetra – an MIT Media Lab spinout recognized worldwide for pioneering smartphone-powered refractions to serve the 4.5B individuals in need of vision correction. It's commonly cited that more than half of said populace remains uncorrected to this day. At EyeNetra, he contributed to the development of 4 products from inception, honed their go-to-market strategy, and architected a successful platform for global growth. Thousands of units were both sold and shipped to eye care professionals in over 90 countries within a span of 36 months. By maintaining lean operations, the company eventually became cash flow positive – a rarity at the intersection of hardware, software, and healthcare in an overcapitalized climate. The team also explored a first of its kind model for teleoptometry and spent years in deep R&D, clinical trials, regulatory approvals, and manufacturing prior to commercialization. Confronted along the way were countless moments fraught with uncertainty including an abundance of failures. To-date, this technology suite has facilitated 5 million refractions and a quarter-million connected exams (and counting). It would be remiss not to mention the smiles conjured of millions more from the friends, families, and caretakers of patients.

WEBVTT

00:00:05.200 --> 00:00:07.870
Welcome to the loud time medtech leaders podcast.

00:00:08.169 --> 00:00:15.029
This is a weekly conversation with med tech leaders who have succeeded in Latin America today.

00:00:15.119 --> 00:00:20.219
Our guest is[inaudible] Modi, founder and CEO of ambition.

00:00:20.679 --> 00:00:22.260
Hey, Raul is great to have you here today.

00:00:22.899 --> 00:00:24.170
Long time in the making.

00:00:24.530 --> 00:00:26.030
Thank you for having me, Julio.

00:00:26.179 --> 00:00:27.440
I'm excited to be here.

00:00:28.100 --> 00:00:28.519
Awesome.

00:00:28.850 --> 00:00:29.960
[inaudible] welcome to the show.

00:00:30.530 --> 00:00:37.490
Well, uh, listeners,[inaudible] is a health tech optimist, serial entrepreneur and biomedical engineer.

00:00:37.640 --> 00:00:46.700
He is the founder and CEO of envision a B2B marketplace for Mobile Diagnostics and care essentials for all.

00:00:46.701 --> 00:01:02.840
Was it director and founding member at eye Nettra and MIT media lab is pinout recognized worldwide for pioneering smartphone powered refractions to serve the 4.5 billion individuals in need of vision correction.

00:01:03.409 --> 00:01:04.370
I need Trump.

00:01:04.459 --> 00:01:16.069
He contributed to the development of four products from inception and he honed their go to market strategy and architected a successful platform for global growth.

00:01:16.670 --> 00:01:17.420
Thanks for this.

00:01:17.569 --> 00:01:25.939
Thousands of units were bought, sold and shipped to eyecare professionals in over 90 countries within a span of 36 months.

00:01:26.120 --> 00:01:34.939
So quite an impressive track record our rail, and really, really honored to have you here and I'm sure listeners will get a lot from this episode of the podcast.

00:01:35.700 --> 00:01:42.689
Well, I appreciate your kind introduction, Julio, and let's hope we can distribute some interesting morsels of wisdom for our listeners.

00:01:43.359 --> 00:01:44.590
That's exactly the idea.

00:01:45.200 --> 00:01:51.519
All right, so let's start with your journey to Latin America or, or how do you get involved with the region?

00:01:52.900 --> 00:01:53.709
Absolutely.

00:01:54.099 --> 00:01:57.310
It was my tenure at eye Nettra that truly kicked off this journey.

00:01:57.311 --> 00:02:10.419
Julio, uh, first and foremost, there was an innate predisposition from day one to serve Latin America because a significant percentage of our company's DNA and talent pool actually hailed from this region, namely from Brazil.

00:02:10.870 --> 00:02:17.139
Furthermore, the very ethos of the company is to extend the reach of care by leveraging mobile technology.

00:02:17.620 --> 00:02:26.169
I think we finally cemented our decision during the GTM planning phases, which is when the opportunity and need in Latin America became obvious.

00:02:26.530 --> 00:02:41.139
More specifically, it was our efforts and the customer discovery activities, studying the macro socioeconomics, conducting ethnographic research and eventual market segmentation that really ultimately supported our decision to embark on.

00:02:41.140 --> 00:02:53.680
This chair and pull you also add that to, although the platform war for a smartphone operating systems was still ongoing at the time of the smartphone itself had already become a ubiquitous instrument in everyday life.

00:02:54.189 --> 00:03:09.310
So much of the early quant and qual data obtained in the states, in India during the iterative phases of prog development, um, seem to really agree with our thesis that we have a place in both developed and developing markets if sequenced properly.

00:03:10.560 --> 00:03:12.030
But again, interesting.

00:03:12.449 --> 00:03:16.020
All right, let's start with some high level discussions here.

00:03:16.469 --> 00:03:16.469
Role.

00:03:16.919 --> 00:03:26.819
Do you see a major trend in Latin America that is relevant to our discussion today in terms of the commercialization of medical devices in the region?

00:03:28.360 --> 00:03:38.469
Certainly I think Latin America is a compelling destination and it's really becoming, you know, the land of opportunity, um, for both clinical trials and commercialization.

00:03:38.770 --> 00:03:46.479
Julio, it's said that the countries of Latin America collectively represent the third largest economy and healthcare spending is on the rise.

00:03:46.480 --> 00:03:50.469
So, you know, I want to believe this holds true across many med tech industries.

00:03:50.800 --> 00:04:04.360
Now keep in mind there is also a large aging population and maybe you know it's not the same predicament as Japan, but the four major non communicable diseases are certainly a culprit here and a contributing factor.

00:04:04.719 --> 00:04:09.819
So naturally this must translate to a favorable environment for clinical trials too.

00:04:10.599 --> 00:04:14.169
They'll, you know, that's not really my area of expertise in Latin America.

00:04:14.409 --> 00:04:25.149
I think big changes to use decades Old Regulatory Framework where the MDR will replace the current MDD, should open many doors in the areas of clinicals.

00:04:25.629 --> 00:04:49.720
Now in my industry, promise exists in a popular citation that says 80% of visual impairment is treatable or preventable and the global vision care and I were market is growing at a CJR of more than three and 8% respectively with expected values to reach north of 74 billion in 265 billion respectively over the next five years.

00:04:49.970 --> 00:04:55.779
And I think around 3 billion plus is attributed to the equipment market alone.

00:04:56.319 --> 00:05:02.290
Now in Latin America, you know, hundreds of millions of people in need of corrective lenses, right?

00:05:02.379 --> 00:05:10.660
And there's also this inequality in the distribution of patients to provide a ratios juxtaposed by a surgeon connectivity and med tech innovation.

00:05:11.110 --> 00:05:25.420
So you can imagine a Leo that the white space is just tremendous with unbounded growth potential and just to keep things in check and be honest for our listeners and maybe temper expectations, it's seldom crystal clear in the trenches.

00:05:25.449 --> 00:05:25.779
Right.

00:05:25.779 --> 00:05:30.790
The irony and challenge in all of this is Latin America is the behemoth market.

00:05:30.790 --> 00:05:40.509
As you know, Julio and making gross generalizations about market behavior usually doesn't hold water on a country to country basis across each and every industry.

00:05:40.990 --> 00:05:42.519
Devil is usually in the details.

00:05:42.521 --> 00:05:50.769
Once your tams and sams are deconstructed and as an entrepreneur you often find yourself grappling with this ambiguity.

00:05:51.250 --> 00:06:00.589
So I often joke career consultants love to offer insights, but let's hop on the line and go for a ride and don't bother bringing your excel spreadsheets and PowerPoint presentations.

00:06:01.129 --> 00:06:02.779
Execute is everything.

00:06:03.250 --> 00:06:03.850
Absolutely.

00:06:03.970 --> 00:06:05.680
Yeah, I agree with the comments.

00:06:05.709 --> 00:06:12.459
Certainly Latin America is a up and coming markets, especially with what's going on with the EMDR.

00:06:13.029 --> 00:06:20.970
And of course we have some chronic decisions that are really, really prevalent in the region and the valley is gonna.

00:06:20.980 --> 00:06:24.459
I mean these two factors are driving the growth of the market.

00:06:24.910 --> 00:06:28.779
So let's get a little deeper arrival in the discussion here.

00:06:29.589 --> 00:06:35.920
So let's speak about practical experience, commercializing medical devices in Latin America.

00:06:36.430 --> 00:06:45.399
I love to hear your thoughts and recommended best practices, but this area in general, so in what countries have you been involved in Latin America row?

00:06:47.430 --> 00:06:54.990
I have hands on experience working with Argentina, Brazil, Columbia, Chile, Mexico and Peru.

00:06:55.279 --> 00:07:01.620
Uh, some markets frankly fared better than others for us, but we amassed many insights and valuable learnings along the way.

00:07:01.920 --> 00:07:12.089
And I'm sure there are several countries in the region where I had no direct contact that are still using our products simply thanks to their low risk, nature, portability and access to the secondary markets.

00:07:12.259 --> 00:07:20.660
But the countries that you mentioned are the top countries in the region, probably 80% or more of the sales of medical devices individually in these countries.

00:07:21.079 --> 00:07:28.160
And certainly Brazilian itself is a huge market, so if you gain experience in Brazil that is very, very valuable for listeners.

00:07:28.970 --> 00:07:31.069
Anyway, so let's get the discussion.

00:07:31.970 --> 00:07:37.310
Your towers, the to market strategy or market access strategy that you had in your previous company.

00:07:37.310 --> 00:07:51.800
I Tra, do you have a proactive and well thought out strategy where you created the market access plan for each country you are planning to enter in Latin America or do you have an opportunistic or reactive approach where you're just waiting for the distributor to contact you?

00:07:53.149 --> 00:07:58.579
Be Proactive and not reactive is a valuable adage but things don't always go as planned.

00:07:59.300 --> 00:08:12.949
So our strategy, visa vi market rollout and penetration was fairly robust at a high level, but I think we were quite green in our ability to prioritize which targets to go after first in this region at a country level.

00:08:13.610 --> 00:08:22.189
Prior to entering Latin America, we launched our device business with the direct preorder campaign actually, which quickly turned into an owner's game of playing catch up.

00:08:22.759 --> 00:08:30.050
I'm trying to juggle supplier relations during our first manufacturing run while tactfully managing customer satisfaction in parallel.

00:08:30.319 --> 00:08:40.100
And this was a grueling lesson for us that said, we were also fortunate to receive plenty of inbound interest early from distributors in key markets, including Latin America.

00:08:41.120 --> 00:08:41.600
Okay.

00:08:41.659 --> 00:08:46.909
So in your opinion, how do you find a distributor in Latin America?

00:08:47.299 --> 00:08:49.100
Where are your tips or best practices?

00:08:51.070 --> 00:08:51.639
Sure.

00:08:51.820 --> 00:09:03.360
I think our strength was navigating trade shows, uh, which are a fantastic opportunity to vet distributors and for that matter, really find them in the first place in the vision care space.

00:09:03.600 --> 00:09:10.620
Any serious player from Latin America will surely be in attendance at the major expos and conferences taking place in the states.

00:09:11.009 --> 00:09:12.269
And even on a budget.

00:09:12.419 --> 00:09:14.940
Walking the floor is a worthwhile exercise.

00:09:15.210 --> 00:09:17.399
Just make sure to do your homework beforehand.

00:09:17.759 --> 00:09:27.899
So we orchestrated frugal marketing campaigns to raise awareness and the dynamic nature of these trade shows, although exhausting at times, promotes plenty of healthy collisions.

00:09:27.900 --> 00:09:37.110
And you'll really discover which distributors are actively seeking novel solutions to diversify their inventory if still unsure at that stage.

00:09:37.179 --> 00:09:42.629
So you can request a references as the next step and even visit their facilities if feasible.

00:09:43.139 --> 00:09:51.210
But for me, due diligence is a slightly different approach for distributors than let's say sourcing a supplier for manufacturing.

00:09:51.809 --> 00:09:54.320
I'm, I'm far more interested in meeting their teams.

00:09:54.321 --> 00:09:59.039
So it's really all about building relationships and empathy is the game, Julio, right?

00:09:59.041 --> 00:10:02.879
It's important to recognize and address their concerns as well.

00:10:02.880 --> 00:10:05.759
And understand that risk is a two sided coin here.

00:10:06.029 --> 00:10:16.799
One more token of wisdom might have in qualifying distributors is don't be myopic and only tempted by those who offer a large po out the gate, right?

00:10:16.801 --> 00:10:21.480
Instead I'd weigh how much of a priority they're willing to really place on your products over the longterm.

00:10:21.860 --> 00:10:25.139
You know, you can ask yourself questions like, where do I fit in their portfolio?

00:10:25.440 --> 00:10:30.149
Is your product complimentary or an innovative standout compared to their other offerings?

00:10:30.150 --> 00:10:33.000
Or is it just another skew next to 10 similar products?

00:10:33.360 --> 00:10:37.830
Why does this distributor want to join forces with you versus your competitor to begin with?

00:10:38.159 --> 00:10:45.690
And is their team savvy enough to offer comprehensive demos and the post sale support that really lives up to your standards?

00:10:45.960 --> 00:10:51.059
So I think these sobering questions will pay dividends down the stretch.

00:10:51.570 --> 00:10:58.679
I would say my final thought is to avoid offering countrywide exclusivity, especially for larger countries.

00:10:58.710 --> 00:10:59.100
Right?

00:10:59.399 --> 00:11:02.279
I'm usually competition breeds performance, I like to say.

00:11:02.639 --> 00:11:12.179
So for us we found joy with smaller to midsize distributors who demonstrated commitment and passion for our products while still offering adequate prior experience.

00:11:12.840 --> 00:11:14.340
You're bringing up a very good points.

00:11:14.350 --> 00:11:22.379
Well in Latin America you find very fragmented markets within every country.

00:11:22.740 --> 00:11:31.289
In other words you have for example a Colombia, my home country you have like five different countries or regions within Columbia.

00:11:31.830 --> 00:11:43.320
So it's just difficult to have a shooter that has nationwide coverage because you also have some geographical restrictions in many countries in Latin America between regions.

00:11:43.559 --> 00:11:57.970
So you have cultural differences, major, very strong cultural differences and it's just difficult to find a shooter can't cover a and can interact culturally among all of these regions.

00:11:58.269 --> 00:12:05.649
So a, it's wise to have in a country like Columbia for example, have a shooter in every region to cover the whole country.

00:12:06.429 --> 00:12:09.070
Cause people like to do business with like minded individuals.

00:12:09.071 --> 00:12:12.220
You know, people who speak the same dialect and things of that nature.

00:12:12.549 --> 00:12:13.210
Spot on.

00:12:13.211 --> 00:12:13.629
Julio.

00:12:13.840 --> 00:12:14.440
Great Advice.

00:12:14.860 --> 00:12:36.909
All right, so did you have a hands off management approach where you just sold products to the shooter and let it do the rest on its own or do you have a hybrid approach where you had a local clinical sales agent or even a local office, our country manager to support the work or the shooter?

00:12:38.289 --> 00:12:42.700
Well, we gave our distributors ample breathing room tackle Nate and operator.

00:12:42.940 --> 00:12:45.700
We kept a pulse and supported them from afar.

00:12:46.179 --> 00:12:52.990
Routinely we would offer training refreshers and periodically check in or furnish mark on materials for them.

00:12:53.350 --> 00:13:03.070
While we did experiment with offices in both NYC and Mumbai at various phases, we ultimately just couldn't justify doing the same in Latin America given our resources.

00:13:03.460 --> 00:13:09.309
So it wasn't a hybrid strategy in the sense of having boots on the ground or opening a local office.

00:13:09.311 --> 00:13:16.870
But we did our very best to support our friends in Latin America remotely, which of course is more practical these days, right.

00:13:16.870 --> 00:13:20.289
With the advent of video conferencing, whatsapp and so on.

00:13:20.590 --> 00:13:27.399
Additionally on the product side, Julio, you know the beauty of mobile app development is we can push software updates from afar.

00:13:27.820 --> 00:13:33.429
Now if you have the means to open a satellite office or even have one or two employees there, all the better.

00:13:33.519 --> 00:13:42.429
Certainly I'm a strategy I can prescribe too, but just set the bar high from day one and establish cogent and lucid communication with your distributors.

00:13:42.590 --> 00:13:43.220
Absolutely.

00:13:43.340 --> 00:13:43.850
Absolutely.

00:13:44.240 --> 00:13:44.659
Yeah.

00:13:44.720 --> 00:13:56.120
Another strategy that companies have guesses, a third strategy role is to have somebody in Miami, they can travel easily to the major countries in Latin America from that location.

00:13:56.330 --> 00:14:15.500
It's just because if you have a company in California and headquarters in California and you're shooters in Peru or Argentina, I mean it's a the time differences, the geographical distance, it just makes it a little difficult, so just letting the shooter on its own, it's probably not always the best.

00:14:15.500 --> 00:14:18.139
So a lot of companies have something in the middle.

00:14:18.140 --> 00:14:31.250
I mean having an office for, of course it's expensive in every major country in that Deacon America or trained to manage their business from California, especially when you don't speak the language Spanish or Portuguese case or Brazil.

00:14:31.549 --> 00:14:38.299
Having personally kind of in the middle of the action in Miami is also an option for many companies.

00:14:38.659 --> 00:14:45.230
And that person usually is a Spanish speaking person who has experience in medical device sales in North America.

00:14:45.230 --> 00:14:54.389
So he can easily travel and have the pulse of the distributors and either whenever they need them and be proactive and visit distributors every so often.

00:14:54.480 --> 00:14:58.529
So they feel that they have the support of the manufacturer always.

00:14:59.230 --> 00:15:00.309
That's great advice.

00:15:00.311 --> 00:15:12.789
And we're also seeing more models and places like Miami where you have master distributors, right, who can have greater reach over larger geographical areas and be that more local interface as you described.

00:15:12.791 --> 00:15:13.960
So couldn't agree more.

00:15:14.509 --> 00:15:16.610
Alright, let's move along here.

00:15:17.360 --> 00:15:19.850
[inaudible] let's switch gears a little bit.

00:15:19.909 --> 00:15:29.750
Now we know in a regulatory approvals and market clearance is a big hurdle for many companies, so I love to expand upon your experiences here.

00:15:30.580 --> 00:15:35.210
Were you involved in this aspect where all getting market clearance in major markets in Latin America?

00:15:36.320 --> 00:15:36.590
Yes.

00:15:37.100 --> 00:15:53.240
Will Yo, I like to say context is key, so let's start by establishing that dinette trows products are a low risk, noninvasive, don't emit radiation or energy in there technically nondiagnostic so we're really talking about a class one framework here.

00:15:53.690 --> 00:15:58.490
Very early on I did receive some class two or three experience briefly.

00:15:58.909 --> 00:16:02.720
However, this was largely limited to DHF activities.

00:16:03.019 --> 00:16:08.720
You know, building my QMS chops and learning to work within design controls and a CGM ps.

00:16:09.080 --> 00:16:18.500
I was not yet exposed at that stage to the process of obtaining international approvals or interfacing with regulatory bodies for market clearance.

00:16:19.100 --> 00:16:37.820
So just as the FDA plans to update its medical device regs pertaining to 21 CFR eight 20 and finally harmonize with ISO 1345 I think it's worth noting that many agencies in Latin America are also refactoring their own requirements.

00:16:38.149 --> 00:16:44.000
Hopefully this will reduce compliance burdens for emerging technologies and smaller companies.

00:16:44.450 --> 00:16:45.379
For us.

00:16:45.500 --> 00:16:56.149
ISO 1345 actually took a bit of a backseat, which in turn became a stumbling block as a hindered our progress with a few international markets outside of Latin America.

00:16:57.190 --> 00:16:57.720
Okay, great.

00:16:58.139 --> 00:17:04.650
So let's dig deeper by country to discuss any tapes or any traps, trouble it when obtaining regulatory approvals.

00:17:05.039 --> 00:17:05.970
What about Mexico?

00:17:06.900 --> 00:17:09.720
Yeah, I think Mexico is a good place to start.

00:17:09.721 --> 00:17:10.829
In our discussion here.

00:17:11.250 --> 00:17:16.920
I believe Mexico is the second largest medical device market in Latin America after Brazil.

00:17:17.549 --> 00:17:32.670
So if your device has already been approved in the u s and Canada and Japan, I believe you may qualify for an equivalency review, which unfortunately does not guarantee a faster approval per se, but it does apply less paperwork.

00:17:33.039 --> 00:17:48.480
I'm also aware that coal for pre, you know the agency there has expanded their list of exempt products in recent years, but simultaneously they've also updated the classification for certain IBDs and US requirements may have increased in some areas and then reduced in others.

00:17:48.779 --> 00:18:03.779
Now, despite a combined GDP exceeding three point 2 trillion with Mexico and Brazil combined, I think you'll agree with this wheel and perhaps something we learned the hard way as a resource constraint startup.

00:18:04.200 --> 00:18:14.250
Historically, both of these markets and Latin America feature a complex regulatory environment and typically they're more cost prohibitive and tend to be lethargic in their timelines.

00:18:14.549 --> 00:18:15.720
Put in gentle words.

00:18:16.470 --> 00:18:17.369
Yeah, I agree.

00:18:17.759 --> 00:18:18.089
All right.

00:18:18.180 --> 00:18:19.049
What about Brazil?

00:18:19.289 --> 00:18:20.609
What do you have to say about it?

00:18:21.240 --> 00:18:23.640
So it seems the tides are turning today.

00:18:23.641 --> 00:18:41.220
I think Brazil, historically they've had a complex system in place where in the past they had the cadastral route for the lower class one class two devices and then you had the registrar route for the class three and then four devices.

00:18:41.730 --> 00:18:53.309
I recall, you know, three to four years back, a statistic that Brazilian regulators rejected nearly half of all registration applications for a class of higher risk devices.

00:18:53.700 --> 00:18:58.349
And that said rejection rate was up almost 15% from the year prior.

00:18:58.740 --> 00:19:12.779
But Julio, I'm hearing these days that at visa Brazil's agency is finally issuing on notification pathway, which provides streamlined market access for lower risk devices and bypasses many of these former requirements.

00:19:13.470 --> 00:19:17.910
Um, so at the time, you know, we were told not to hold our breath, this was a few years ago.

00:19:18.240 --> 00:19:21.359
If these changes do go in effect this year, I think that's excellent news.

00:19:21.361 --> 00:19:21.839
Indeed.

00:19:22.230 --> 00:19:33.180
I'm an, I hear that the documentation requirements will be similar to the existing class one pathway, but you get to avoid all of the deeper technical reviews.

00:19:33.539 --> 00:19:41.279
So they'll have some kind of notification within a month or so after the agency, you know, receives the submission and, and fees.

00:19:42.029 --> 00:19:42.420
Okay.

00:19:42.599 --> 00:19:43.109
Very good.

00:19:43.460 --> 00:19:43.779
All right.

00:19:43.799 --> 00:19:44.670
What about Columbia?

00:19:45.509 --> 00:19:45.779
Yeah.

00:19:45.780 --> 00:19:51.029
Looking back, I probably hang my hat in Columbia to mainly avoid many of these speed bumps.

00:19:51.450 --> 00:19:57.960
So Columbia has nearly 50 million residents and is a very attractive market.

00:19:58.529 --> 00:20:14.460
Their agency, as you know in Vima has implemented a four tiered classification system that's very similar I believe to the EU of yesteryears and in Vima automatically approves class one and two way applications and generates a certificate.

00:20:14.819 --> 00:20:18.509
And just over a week so you can almost begin selling immediately.

00:20:18.900 --> 00:20:31.920
And then I think within 90 days for some of the other classes, they'll get back to you, of course agency will still review on the app and respond to any questions and then have some requirements set forth.

00:20:32.329 --> 00:20:43.680
Time frame has really a truncated and I think that overall just the timelines could be expedited with registrations valid for a decade, if not mistaken.

00:20:44.460 --> 00:20:49.789
So you know, once in FEMA does receive your, it tends to get renewed a lot quicker.

00:20:50.119 --> 00:21:02.630
Now as a cautionary tale, Julio foreign medical device manufacturers that don't have a physical location in Columbia or Brazil must appoint a local registration holder or importer of record.

00:21:03.349 --> 00:21:14.119
Now if you choose your distributor as your importer of record, um, you'll only be limited to that one distributor in the region and transferring is a complete headache.

00:21:14.569 --> 00:21:21.589
So it's advisable to choose a third party logistics operator or independent legal rep if you can.

00:21:21.980 --> 00:21:24.589
And you know, otherwise your distributor may claim ownership.

00:21:25.009 --> 00:21:25.599
Great points.

00:21:25.910 --> 00:21:27.079
Well, yes, exactly right.

00:21:27.509 --> 00:21:28.519
All right, what about Peru?

00:21:29.720 --> 00:21:30.230
Sure.

00:21:30.230 --> 00:21:34.730
So the Peruvian government has rolled out a laundry list of updates over the years.

00:21:35.019 --> 00:21:40.279
I'm including an initiative to reduce approval timeframes by approximately 30 days.

00:21:40.579 --> 00:21:46.309
So with faster reviews, I think they've also simplified the process and reduce the burden of requirements.

00:21:46.700 --> 00:21:52.069
But I think they also have a lot less.

00:21:52.849 --> 00:22:02.569
So Peru has also reduced a lot of their manufacturing flowchart requirements and other documents such as clinical trial reports in lieu of the raw data.

00:22:02.570 --> 00:22:07.220
So I think Peru is a promising place to look at.

00:22:07.221 --> 00:22:11.839
But another good bet to really grease the wheels is Argentina in my opinion.

00:22:12.170 --> 00:22:18.500
I think Argentina is slightly less populous than Columbia, but it outputs more than two x the GDP.

00:22:18.980 --> 00:22:24.890
And Matt, the Argentinian medical device regulator will accept a cfs or CFG.

00:22:25.130 --> 00:22:26.480
I'm blessed by the FDA.

00:22:26.480 --> 00:22:28.519
So you know, that makes life a lot easier.

00:22:29.059 --> 00:22:37.819
Now, Argentina is a member of Merkel sewer and I think they've used requirements for class one dossier as well a while back.

00:22:38.359 --> 00:22:44.059
So I think all these things in consideration, um, Argentina and Peru should definitely be on the map.

00:22:44.420 --> 00:22:44.839
Yes.

00:22:45.230 --> 00:22:45.480
All right.

00:22:46.190 --> 00:22:47.210
That's one a chili.

00:22:48.589 --> 00:22:49.009
Sure.

00:22:49.010 --> 00:22:54.589
I think Chili is another country where frankly we missed the boat in a way.

00:22:55.160 --> 00:23:05.289
Um, I engaged in early diligence with one or two parties but was not patient and didn't invest the proper time to source a fit distributor there.

00:23:05.960 --> 00:23:12.410
Chile is one of the more dynamic economies in the region and they actually have uh, a friendly import climate.

00:23:13.109 --> 00:23:19.430
Um, that doesn't require a sanitary registration in most instances or perhaps they have a voluntary submission.

00:23:20.180 --> 00:23:32.869
So, um, I think with the free trade agreements put in place more than a decade ago and just the environment of importation, I think it's a very friendly place to look at and do.

00:23:32.871 --> 00:23:36.950
Keep in mind, you know, there is another things that will drum up the fees.

00:23:36.950 --> 00:23:40.339
But my thing, chili is an interesting region without a doubt.

00:23:40.490 --> 00:23:49.369
I would say Julio has a capsule summary Search for the path of least resistance beginning this journey and don't try to boil the ocean at once.

00:23:49.849 --> 00:23:50.269
Right.

00:23:50.750 --> 00:23:57.230
Ranks can be a black box due to the language barriers, cultural nuances and the bureaucracy.

00:23:57.859 --> 00:24:09.470
Yet, you might occasionally hear a nightmare story or two o' folks wrestling with approvals for years or being a victim of resource depletion due to the cost recovery model of some developing countries.

00:24:09.471 --> 00:24:18.019
But here's the plug a reputated cro like yours, Julio can facilitate in a big way and really assist in navigating the waters.

00:24:18.020 --> 00:24:23.289
So ask for help and remember to always use a third party registration hold there.

00:24:23.549 --> 00:24:24.569
Very well said.

00:24:24.599 --> 00:24:25.470
Yeah, that's true.

00:24:26.859 --> 00:24:41.099
Alright, uh, let's switch gears a little bit and let's speak about demand generation in detail role where you involved in strategies and tactics to increase demand from the end user and ultimately sales.

00:24:42.400 --> 00:24:42.880
Sure.

00:24:42.881 --> 00:24:51.519
So now that we've established it was not a traditional hybrid model, akin to a multinational with vast firing power.

00:24:51.859 --> 00:24:54.460
Um, let's unpack a bit how we fueled end user demand.

00:24:54.461 --> 00:25:00.759
As a startup company, typically strategy is formed above the shoulders and tactics below.

00:25:01.119 --> 00:25:14.049
So for a tangible, mobile intriguing product like ours in a sea of Dolan, antiquated equipment that might be better suited in a museum than a trend, the optical shop marketing was really our growth engine.

00:25:14.500 --> 00:25:16.869
So don't diminish the marketing department's role.

00:25:16.871 --> 00:25:19.720
Julio, keep in mind your four ps and three Cs.

00:25:20.049 --> 00:25:36.309
So for us it was paramount to identify where the undervalued attention was, know your customer first and foremost, and then work to raise awareness and awareness can be a two pronged activity that's aimed at both the patient and the provider.

00:25:36.880 --> 00:25:45.009
I think part and parcel to this effort is discovering your key opinion leaders and more practically speaking, finding your product champions.

00:25:45.279 --> 00:25:51.160
So build a list and with digital marketing and social media content is your currency.

00:25:51.339 --> 00:25:57.279
Leveraging these platforms is the tactic to really balance or your inside and outside sales endeavors.

00:25:57.640 --> 00:26:04.269
Just keep experimenting to see what's working for your organization and it doesn't have to be expensive, right?

00:26:04.270 --> 00:26:07.660
Stay Frugal or better yet, aim for free where possible.

00:26:08.319 --> 00:26:16.299
Now, I understand Instagram may not seem ideal for a hematology product or an invasive device, but you might also be surprised.

00:26:16.990 --> 00:26:27.789
Then finally, I like to say cultural ads may seem nice, but please be careful with your marketing claims and your cost of sale shouldn't outstrip your margins.

00:26:28.119 --> 00:26:33.009
So just be sure of this and don't fall victim to the growth at all costs mentality.

00:26:33.279 --> 00:26:35.680
That's so pervasive in VC La la land.

00:26:36.589 --> 00:26:37.369
Okay.

00:26:37.490 --> 00:26:38.210
Very good.

00:26:39.059 --> 00:26:40.819
Uh, well what about pricing?

00:26:40.970 --> 00:26:44.369
Do you feel that the Americans are very price sensitive region?

00:26:45.240 --> 00:26:54.569
While price sensitivity varies by country in the region, it's still very much a function of product placement and positioning within your given market.

00:26:55.259 --> 00:27:02.910
More sophisticated and niche technology can command higher prices of course from top tier hospitals and reputated institutions.

00:27:03.299 --> 00:27:11.849
Conversely, more hackneyed propositions might face competition from Asia or even local companies which will drive down prices.

00:27:12.420 --> 00:27:16.710
But if there's nothing proprietary or novel, your exposure increases.

00:27:17.430 --> 00:27:29.970
So I also hear some industries such as Pharma are vulnerable to government tender processes which implement specific guidelines, but maybe that's not a bad thing in the best interests of patients.

00:27:30.569 --> 00:27:36.660
And finally, currency volatility and the forex climate is yet another hurdle in Latin America.

00:27:37.650 --> 00:27:45.180
Um, I think manufacturers can implement controls such as map and RRP and their contracts just to eliminate some of this turbulence.

00:27:45.960 --> 00:27:52.289
You know, at Tai Nettra the utility of our products wasn't unique per say in terms of outputting refraction data.

00:27:52.740 --> 00:27:58.019
Many devices can do that, but we competed heavily on price and innovative industrial design.

00:27:58.589 --> 00:28:13.200
So affordability and accessibility was actually our value proposition, um, since traditional equipment costs in order of magnitude more, um, without the added benefits of portability and connectivity, although right.

00:28:13.201 --> 00:28:17.369
Competition is inevitable and it did come knocking and due course.

00:28:18.000 --> 00:28:18.509
Sure.

00:28:19.279 --> 00:28:19.740
All right.

00:28:20.539 --> 00:28:22.950
Any experience on the reimbursement side of the spectrum?

00:28:23.369 --> 00:28:26.309
Yeah, I don't have much intel in this arena.

00:28:26.369 --> 00:28:33.839
I can only imagine that the fragmented landscape with multiple healthcare systems in Latin America adds a layer of complexity there.

00:28:34.500 --> 00:28:46.470
But perhaps it's most efficient to first target those countries with a single payer system or a centralized public insurer, maybe like eps and Colombia flanked by private plans.

00:28:47.069 --> 00:28:56.460
So pitching the merits of your product to government bodies might help really shape the healthcare policy there and create a framework that promotes innovation.

00:28:56.849 --> 00:29:03.599
And then later you can target insurance carriers and hospital networks and the private sector to broaden your reach.

00:29:03.869 --> 00:29:25.230
I recall spearheading an effort in Mexico to try educating the government stakeholders and employees and the public sector about the importance of regular vision screenings and it was rudimentary and short lived, but the thought of deploying a service model using technology like ours is interesting and may create value with minimal disruption to their workflow.

00:29:25.470 --> 00:29:31.410
I also know of people trying similar models here in the states by leveraging high footfall settings.

00:29:32.250 --> 00:29:35.490
Imagine conducting office visits for a big employer, for example.

00:29:35.819 --> 00:29:38.759
But frankly I'm unsure how scalable this is for a startup.

00:29:38.760 --> 00:29:48.369
Assuming high cacas and, and even if not labor intensive, more sophisticated telemedicine setups can become capital intensive over time.

00:29:48.549 --> 00:29:49.390
Yeah, sure.

00:29:50.109 --> 00:29:50.109
Alright.

00:29:50.319 --> 00:29:54.069
Any input tour tips regarding the imputation process in the region?

00:29:54.759 --> 00:29:55.269
Yes.

00:29:55.270 --> 00:29:58.839
Be transparent with both your customers and your distributors.

00:29:59.559 --> 00:30:07.509
Importation fees such as Vats and duties are not insignificant and you should carefully consider them in your pricing strategy.

00:30:08.140 --> 00:30:10.960
I think higher volumes may offer some savings, right?

00:30:10.961 --> 00:30:21.309
Due to unit level discounts, but just make sure whomever is on the receiving end is cognizant of these indirect costs and is able to coordinate all the logistics involved.

00:30:21.609 --> 00:30:35.380
I believe Brazil has simplified the importation process to a degree with a fairly new provision that no longer requires medical devices to undergo inspections at the point of entry, which will save both time and money.

00:30:36.400 --> 00:30:42.549
So you know, easing importation for foreign manufacturers with a good compliance history should become a trend.

00:30:42.789 --> 00:30:48.460
Fingers crossed and I do see many of these countries making slow but steady net positive progress here.

00:30:48.619 --> 00:30:49.220
Excellent.

00:30:49.309 --> 00:30:49.670
Good.

00:30:50.059 --> 00:31:00.500
All right, so what's your experience with corruption or bribery individually in light of the Foreign Corrupt Practices Act of 1997 1977 I believe.

00:31:01.519 --> 00:31:02.119
1977 I'm sorry.

00:31:02.150 --> 00:31:02.930
Thank you for that.

00:31:05.259 --> 00:31:10.839
So no incidents come to mind, but yes, Dave vigilant and be aware of its implications.

00:31:11.470 --> 00:31:22.630
Although the FCPA is often associated with public issuers of securities rather than private companies, I think private companies are also susceptible to law enforcement interests.

00:31:23.200 --> 00:31:28.630
Forgive me if I'm mistaken, but private companies are still subject to the anti-bribery provisions.

00:31:28.690 --> 00:31:30.549
If not the accounting requirements.

00:31:30.849 --> 00:31:42.460
So civil and criminal enforcement by the Deo j still applies here and in regions marred by political unrest and unstable socioeconomic climate.

00:31:42.910 --> 00:31:44.529
These things can and do happen.

00:31:44.530 --> 00:31:46.450
So just are on the side of caution.

00:31:46.819 --> 00:31:48.079
Yes, that's true.

00:31:48.900 --> 00:31:53.000
All right, we are close to the end of the show.

00:31:53.720 --> 00:31:53.720
[inaudible].

00:31:54.019 --> 00:32:01.640
Before we sign off today, do you have any final thoughts, morsels of wisdom or other museums for our listeners?

00:32:01.970 --> 00:32:12.200
What would you say to a small or midsize med tech company that hasn't looked at Latin America or it's just starting to explore the region as a potential market to expand its footprint?

00:32:12.920 --> 00:32:15.140
Even if you fell asleep during this podcast.

00:32:15.279 --> 00:32:21.380
And must be clear by now that I'm bullish and optimistic about Latin America despite any inherent challenges.

00:32:21.769 --> 00:32:35.420
So let's end on a more philosophical note, whether you're jumping down the rabbit hole of Med tech innovation and life sciences for the first time or desperately trying to climb out whether a novice or a battle tested veteran.

00:32:35.779 --> 00:32:43.670
I implored that you not only do in tri, but also pause along your journey to reflect and ask yourself why.

00:32:44.299 --> 00:32:45.980
Remember to prioritize your happiness.

00:32:45.980 --> 00:32:46.490
Always.

00:32:46.730 --> 00:32:48.079
That's where the magic lies.

00:32:49.099 --> 00:32:51.589
And I don't say this from an ivory tower.

00:32:51.779 --> 00:32:58.519
This is also a reminder to myself, something I'm working towards and find myself ruminating about often.

00:32:58.849 --> 00:33:04.730
So don't only pursue what society or family expects of you joining you today is a privilege.

00:33:04.730 --> 00:33:08.569
Julio, thanks so much for having me and launching this initiative.

00:33:09.019 --> 00:33:13.009
Let's make sure to stay in touch and I welcome the audience to reach out as well.

00:33:13.670 --> 00:33:14.089
Excellent.

00:33:14.140 --> 00:33:14.569
If I will.

00:33:14.930 --> 00:33:15.319
Yeah.

00:33:15.380 --> 00:33:16.910
What can the audience French here?

00:33:17.869 --> 00:33:18.289
Sure.

00:33:18.290 --> 00:33:21.829
So feel free to email me at Rohal.

00:33:21.830 --> 00:33:26.569
That's R H U l at envision dot B, z.

00:33:27.109 --> 00:33:28.220
That's e n v.

00:33:28.221 --> 00:33:28.730
I s.

00:33:28.819 --> 00:33:29.029
I.

00:33:29.030 --> 00:33:29.450
O n.

00:33:29.750 --> 00:33:30.289
Dot.

00:33:30.349 --> 00:33:31.130
B.

00:33:31.130 --> 00:33:31.130
Z.

00:33:32.299 --> 00:33:32.630
Okay.

00:33:32.869 --> 00:33:33.920
Very good role.

00:33:34.039 --> 00:33:44.539
I thank you also for your time, for your contribution to our podcast and I'm sure listeners get a lot out of your wisdom or your experience in Latin America.

00:33:44.750 --> 00:33:45.619
Thank you so much.

00:33:45.890 --> 00:33:47.000
Great having you here today.

00:33:47.299 --> 00:33:47.930
My pleasure.

00:33:47.931 --> 00:33:49.609
I wish you and your listeners all the best.

00:33:49.640 --> 00:33:50.150
Ciao.

00:33:50.509 --> 00:33:51.109
Ciao.

00:33:51.200 --> 00:33:51.319
Bye.

00:33:51.320 --> 00:33:51.650
Bye.